Pharma BD Deal Intelligence
Akorn Inc. / Hi-Tech Pharmacal Co. Inc.
2013 · Acquisition/Merger · $640M · Complete
Announcement Sentiment
83
Strongly positive
Akorn to acquire Hi-Tech Pharmacal at $43.50/share cash (~$640M; 23.5% premium); $15-20M expected annual synergies; expanded sterile/specialty generic dosage form capabilities.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Assessment window: 10yr post-close.
Key facts
- Announced Aug 26, 2013
- Closed Apr 17, 2014
- Deal value $640M
- Deal type Acquisition/Merger
- Therapeutic area Generic prescription / OTC
- Indications Generic prescription / OTC
- Key assets Difficult-to-manufacture generic dosage forms (oral solutions, ophthalmic, otic, nasal)
- Mechanism Mixed generic specialty dosage forms
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals